Population pharmacokinetic analysis of micafungin in Japanese patients with fungal infections.

Kenji Tabata, Masataka Katashima, Akio Kawamura, Atsunori Kaibara, Yusuke Tanigawara

Research output: Contribution to journalArticlepeer-review

22 Citations (Scopus)


The object of this analysis was to develop a population pharmacokinetic model of micafungin, a new anti-fungal agent of the echinocandin class, to optimize dosing in Japanese patients with fungal infections. Population pharmacokinetics parameters were determined using NONMEM based on pharmacokinetic data from 198 subjects in seven clinical studies, comprising four phase I, two phase II and one pediatric phase III study. The healthy subjects received intravenous infusion of 2.5-150 mg micafungin. Adult and pediatric patients, age range of 8 month to 15 yeras old, were received 25-150 mg and 1-6 mg/kg daily, respectively. A total of 1825 micafungin plasma samples were available for this analysis. Two-compartment pharmacokinetic model was adopted. The clearance of micafungin was influenced by body weight in children and platelet counts (PLT). However the PLT accounted for less than 20% of the variation of micafungin clearance in Japanese subjects. In conclusions, body weight is the primary covariate factor in pediatric patients. The dose adjustment by body weight would be required only pediatric patients for the micafungin therapy in Japanese patients with fungal infection.

Original languageEnglish
Pages (from-to)324-331
Number of pages8
JournalDrug Metabolism And Pharmacokinetics
Issue number4
Publication statusPublished - 2006 Aug
Externally publishedYes

ASJC Scopus subject areas

  • Pharmacology
  • Pharmaceutical Science
  • Pharmacology (medical)


Dive into the research topics of 'Population pharmacokinetic analysis of micafungin in Japanese patients with fungal infections.'. Together they form a unique fingerprint.

Cite this